Press Releases

Press Releases

Search by keywords:

184 Press Releases found

Large International Study Is Advancing Precision Medicine for Men with Advanced Prostate Cancer

An international collaboration of researchers is advancing precision medicine for men with advanced prostate cancer.

  • Thursday, May 21, 2015

Memorial Sloan Kettering Cancer Center Receives Record Gift of $150 million from David Koch for Innovative Patient Care Facility

Memorial Sloan Kettering Cancer Center announced that it has received the largest gift in its history, a commitment of $150 million from long-time MSK board member David H. Koch. This unprecedented contribution will transform cancer care with a state-of-the-art outpatient medical facility to be known as The David H. Koch Center for Cancer Care. The new center will provide the most advanced cancer treatments in a dynamic space designed with the needs of patients firmly in mind.

  • Wednesday, May 20, 2015

Memorial Sloan Kettering Cancer Center “Specializes in You” with an Innovative and Personalized Digital Landscape

Memorial Sloan Kettering Cancer Center introduced a new, consumer-friendly web presence for www.mskcc.org (Memorial Sloan Kettering Cancer Center) and www.sloankettering.edu (Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center), featuring an innovative platform and on-demand navigation for patients, caregivers, researchers, healthcare professionals, and graduate students, among other core audiences.

  • Tuesday, May 5, 2015

Two Promising Memorial Sloan Kettering Studies Featured at American Association for Cancer Research Annual Meeting

Two encouraging Memorial Sloan Kettering Cancer Center (MSK) studies were featured in this year’s American Association for Cancer Research (AACR) Annual Meeting press program.

  • Tuesday, April 21, 2015

Research Proves Combination Immunotherapy Significantly More Effective than Ipilimumab Alone for Patients with Advanced Melanoma

Positive results from a clinical trial published in The New England Journal of Medicine show that the combination of the immunotherapy drugs ipilimumab (Yervoy) and nivolumab (Opdivo), produced significantly better outcomes than ipilimumab alone in patients with advanced melanoma. A second piece in the same issue from MSK details a dramatic response occurring after a single dose of the combination therapy.

  • Monday, April 20, 2015

Memorial Sloan Kettering Opens Pediatric CAR T Cell Clinical Trial

Researchers from Memorial Sloan Kettering Cancer Center (MSK) are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today, chimeric antigen receptor (CAR) T cells.

  • Thursday, April 9, 2015

Some Cancer Clinics Spend Thousands More Per Patient in Medicare Dollars

The quantity of tests and treatments a cancer patient undergoes could depend largely on where he or she receives care, according to an analysis by researchers at Memorial Sloan Kettering (MSK).

  • Monday, April 6, 2015

Memorial Sloan Kettering Debuts New Mobile Application for Patients

Memorial Sloan Kettering Cancer Center (MSK) has debuted MyMSK, a new mobile application. The app, compatible with iPad, iPhone, and all iOS devices, allows MSK patients to quickly and easily access their lab and radiology results, view their upcoming appointments, record their medications and symptoms in online diaries, communicate with their healthcare team, and more.

  • Monday, February 23, 2015

Memorial Sloan Kettering Cancer Center and Weill Cornell to Co-Lead Tuberculosis Research Unit

In an effort to stop tuberculosis (TB) from becoming progressively less treatable worldwide, the National Institutes of Health is funding a research collaboration among six institutions in close alliance. The total funding, provided by the National Institute of Allergy and Infectious Diseases, could be up to $45.7 million over seven years.

  • Wednesday, February 18, 2015

Memorial Sloan Kettering Study Shows New Kind of Targeted Drug Has Promise for Leukemia Patients

A new type of cancer therapy that targets an oncometabolite produced dramatic results in patients with advanced leukemia in an early-phase clinical trial.

  • Sunday, December 7, 2014